 This will be a multicenter, randomized, placebo-controlled, parallel group study in up to 80 sites in the United States of America USA and Canada to evaluate the efficacy and safety of a fixed dose of SC BMT versus placebo on an as-needed basis under conditions of home use in premenopausal women with HSDD with or without decreased arousal. 